Financials, valuation and sell-side divergence — Consensus $1104-1350 PT reinforces vs HSBC Sell; $1T cap paths eyed
Key Questions
What are the projected financials for Eli Lilly in FY2025 and FY2026?
FY2025 projections are $65.2B in revenue and $24.21 EPS. FY2026 estimates are $80-83B in revenue and $33.5-35 EPS, which have been confirmed.
How did Eli Lilly perform in Q1 with revenue and EPS?
Q1 actual results showed $19.29B in revenue and $7.54 EPS, beating expectations. This contributed to an 86% EPS surge noted in related reports.
What is the current stock price range and YTD performance for Eli Lilly?
The stock trades in the $907-963 range with $932 volume, following a pullback from $1132. It is down 13% YTD.
What is the consensus analyst price target for Eli Lilly?
The median price target is $1250, with ranges from $1104-1350. Specific targets include Leerink at $1104 (Outperform), BofA at $1294, and Bernstein at $1300.
Which analysts have divergent views on Eli Lilly stock?
HSBC has a Sell rating at $850, contrasting with consensus. AI models range $1024-1076, TIKR at $1814, CFRA Buy, and WS Zen at $1222.
What is the potential upside for Eli Lilly stock based on analyst targets?
From current levels around $932, there is 29%+ upside to the median $1250 target. Stable estimates and heavy Zacks searches support this outlook.
What recent analyst actions have occurred for Eli Lilly?
Leerink upgraded on obesity drug coverage expansion. CFRA lowered to Buy from Strong Buy, while some funds like IMS boosted holdings.
How do AI models view Eli Lilly's valuation?
AI models diverge, with some seeing premium growth and others priced-for-perfection risks, ranging $1024-1076. This reflects growth strength meeting high valuation.
FY2025 $65.2B/EPS $24.21; FY26 $80-83B/EPS $33.5-35 confirmed; Q1 actual $19.29B rev/$7.54 EPS beat; stock $907-963/$932 vol (pullback from $1132, -13% YTD); PTs med $1250 (Leerink $1104 Outperform/BofA $1294/Bernstein $1300/Scotiabank) vs HSBC $850 Sell/AI models $1024-1076/TIKR $1814/CFRA Buy; WS Zen $1222; Zacks heavy searches/stable ests; 29%+ upside.